India Pharma Outlook Team | Saturday, 26 July 2025
India's drug and pharmaceutical exports have increased by 92%, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, thanks to a number of initiatives the Center is implementing to realize the vision of Aatmanirbhar Bharat in the pharmaceutical sector, the Parliament was informed on Friday.
In a written response to a question, Minister of State for Chemicals and Fertilizers Anupriya Patel informed the Lok Sabha that the programs include the Strengthening of Pharmaceutical Industry scheme, the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the PLI Scheme for Bulk Drugs, the Scheme for Promotion of Bulk Drug Parks, and the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme.
With an initial investment of Rs 5,000 crore, the PRIP scheme aims to shift the growth of India's Pharma MedTech industry from cost-based to innovation-based by bolstering research and encouraging industry-academia collaboration for research and development in priority areas in medical devices and drug discovery and development. According to her, seven Centers of Excellence (CoEs) have been established under this program.
By boosting production and investment in the pharmaceutical industry and promoting product diversification to high-value items, the PLI Scheme for Pharmaceuticals seeks to improve India's manufacturing capabilities.
Also Read: Biosimilars Set to Drive India's USD 1 Trillion Pharma Export Dream
According to the minister, the program has made it possible to increase investment and production in qualified goods. With a total investment of Rs 37,306 crore by the scheme's third year and cumulative sales of approved products of Rs 2,66,528 crore, including exports of Rs 1,70,807 crore, the committed investment of Rs 17,275 crore targeted over the scheme's six-year period stands significantly exceeded as of March 2025.
